Nickolas A Neitzel

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 3

Top Topics

High Throughput

Protein Protein

Top Venues

ACS medicinal chemistry letters

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander E Drilon, Manish R Sharma, Melissa Lynne Johnson, Timothy Anthony Yap, Shirish M Gadgeel, Dale Nepert, Gang Feng, Micaela B Reddy, Allison S Harney, Mohamed S A Elsayed, Adam W Cook, Christina E Wong, Ronald J Hinklin, Yutong Jiang, Eric N Brown, Nickolas A Neitzel, Ellen R Laird, Wen-I Wu, Anurag Singh, Ping Wei, Keith A Ching, John J Gaudino, Patrice A Lee, Dylan P Hartley, S Michael Rothenberg
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer discovery (2023)
Mohamed S A Elsayed, James F Blake, Mark L Boys, Eric Brown, Bruno D Chapsal, Mark J Chicarelli, Adam W Cook, Jay B Fell, John P Fischer, Lauren Hanson, Christine Lemieux, Matthew C Martinson, Joseph McCown, Oren T McNulty, Macedonio J Mejia, Nickolas A Neitzel, Jennifer N Otten, Martha E Rodriguez, Daniel Wilcox, Christina E Wong, Yeyun Zhou, Ronald J Hinklin
Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors. ACS medicinal chemistry letters 14 (12) (2023)
Mohamed S A Elsayed, James F Blake, Mark L Boys, Eric Brown, Bruno D Chapsal, Mark J Chicarelli, Adam W Cook, Jay B Fell, John P Fischer, Lauren Hanson, Christine Lemieux, Matthew C Martinson, Joseph McCown, Oren T McNulty, Macedonio J Mejia, Nickolas A Neitzel, Jennifer N Otten, Martha E Rodriguez, Daniel Wilcox, Christina E Wong, Yeyun Zhou, Ronald J Hinklin
Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors. ACS medicinal chemistry letters 14 (12) (2023)